Overview

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

Status:
Completed
Trial end date:
2017-02-23
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the effects of esketamine on QT/QTc intervals and electrocardiogram (ECG) morphology at therapeutic exposures of esketamine and noresketamine (intranasal administration) and supratherapeutic exposures of esketamine (intravenous administration) in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Esketamine
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination